You just read:

Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017

News provided by

Boston Biomedical, Inc.

03 Jun, 2017, 09:00 ET